Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice

Clinical and Vaccine Immunology

Volumn 18, Issue 2, 2011, Pages 289-297

  Watson, Douglas S ^a,b   Platt, Virginia M ^a,c   Cao, Limin ^a,d   Venditto, Vincent J ^a   Szoka Jr , Francis C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SRI INTERNATIONAL   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d Changzhou 21st Century Biotechnology Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ASPARAGINYLGLUTAMYLGLUTAMINYLGLUTAMYLLEUCYLLEUCYLGLUTAMYLLEUCYLASPARTYLLYSYLTRYPTOPHYLALANYLSERYLLEUCYLTRYPTOPHYLASPARAGINYLGLYCYLGLYCYLLYSYL BIOTIN; ASPARAGINYLGLUTAMYLGLUTAMINYLGLUTAMYLLEUCYLLEUCYLGLUTAMYLLEUCYLASPARTYLLYSYLTRYPTOPHYLALANYLSERYLLEUCYLTRYPTOPHYLASPARAGINYLGLYCYLGLYCYLLYSYLCYSTEINYLHISTIDYLGLUTAMYLMETHIONYLSERINE; ASPARAGINYLGLUTAMYLGLUTAMINYLGLUTAMYLLEUCYLLEUCYLGLUTAMYLLEUCYLASPARTYLLYSYLTRYPTOPHYLALANYLSERYLLEUCYLTRYPTOPHYLASPARAGINYLGLYCYLGLYCYLLYSYLGLYCYLGLYCYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDINE; BIOTIN TRYPTOPHYLGLYCYLGLYCYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLGLYCINE; GLYCOPROTEIN GP 41; LIPID LINKED NITRILOTRIACETIC ACID; LIPOSOME; MALEIMIDE TRYPTOPHYLGLYCYLGLYCYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLHISTIDYLGLYCINE; NITRILOTRIACETIC ACID; OVALBUMIN; POLYHISTIDINE TAG; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CHELATION; CONJUGATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG DELIVERY SYSTEM; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIGENS; FEMALE; HISTIDINE; HIV ENVELOPE PROTEIN GP41; LIPOSOMES; MICE; MICE, INBRED BALB C; NITRILOTRIACETIC ACID; OVALBUMIN; PEPTIDES; PROTEIN BINDING; VACCINES, SUBUNIT;

EID: 79551484750     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00425-10     Document Type: Article

References (50)

1. Aguilar, J., and E. Rodriguez. 2007. Vaccine adjuvants revisited. Vaccine 25:3752-3762.
2. Alam, S. M., et al. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1-envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178:4424-4435.
3. Altin, J. G., et al. 2006. Synthesis of NTA3-DTDA - a chelator-lipid that promotes stable binding of His-tagged proteins to membranes. Aust. J. Chem. 59:302-306.
4. Alving, C., and M. Rao. 2008. Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine 26:3036-3045.
5. Alving, C. R., V. Koulchin, G. M. Glenn, and M. Rao. 1995. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 145:5-31.
6. Bell, S., and B. Vallee. 2009. The metallothionein/thionein system: an oxidoreductive metabolic zinc link. Chembiochem 10:55-62.
7. Boyle, J., J. Brady, and A. Lew. 1998. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 392:408-411.
8. Brunel, F., A. Darbouret, and J. Ronco. 1999. Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Vaccine 17:2192-2203.
9. Chikh, G., W. Li, M. Schutze-Redelmeier, J. Meunier, and M. Bally. 2002. Attaching histidine-tagged peptides and protein to lipid-based carriers through use of metal-ion-chelating lipids. Biochim. Biophys. Acta 1567:204-212.
10. Cooper, H., et al. 1987. Site-directed chemical modification of horse cytochrome c results in changes in antigenicity due to local and long-range conformational perturbations. J. Biol. Chem. 262:11591-11597.
11. Dal Monte, P., and F. Szoka, Jr. 1989. Antigen presentation by B cells and macrophages of cytochrome c and its antigenic fragment when conjugated to the surface of liposomes. Vaccine 7:401-408. (Pubitemid 19252622)
12. Dal Monte, P., and F. Szoka, Jr. 1989. Effect of liposome encapsulation on antigen presentation in vitro. Comparison of presentation by peritoneal macrophages and B cell tumors. J. Immunol. 142:1437-1443.
13. Dietrich, C., L. Schmitt, and R. Tampe. 1995. Molecular organization of histidine-tagged biomolecules at self-assembled lipid interfaces using a novel class of chelator lipids. Proc. Natl. Acad. Sci. U. S. A. 92:9014-9018.
14. Doyle, H., and M. Mamula. 2001. Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol. 22:443-449. (Pubitemid 32709979)
15. Ernst, W., et al. 2006. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24:5158-5168.
16. Fox, E., R. Waldman, M. Wittner, A. Mauceri, and A. Dorfman. 1973. Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers. J. Clin. Invest. 52:1885-1892.
17. Friede, M., and M. Aguado. 2005. Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems. Adv. Drug Deliv. Rev. 57:325-331.
18. Glenny, A., C. Pope, H. Waddington, and V. Wallace. 1926. The antigenic value of toxoid precipitated by potassium-alum. J. Pathol. Bacteriol. 29:38-45.
19. Gupta, R., and G. Siber. 1995. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 13:1263-1276.
20. Harmon, P., et al. 1997. The release and detection of endotoxin from liposomes. Anal. Biochem. 250:139-146.
21. Huang, Z., P. Hwang, D. S. Watson, L. Cao, and F. C. Szoka. 2009. Tris-nitrilotriacetic acids of subnanomolar affinity toward hexahistidine tagged molecules. Bioconjug. Chem. 20:1667-1672.
22. Huang, Z., J. Park, D. Watson, P. Hwang, and F. Szoka. 2006. Facile synthesis of multivalent nitrilotriacetic acid (NTA) and NTA conjugates for analytical and drug delivery applications. Bioconjug. Chem. 17:1592-1600.
23. Kamala, T. 2007. Hock immunization: a humane alternative to mouse foot-pad injections. J. Immunol. Methods 328:204-214. (Pubitemid 350017755)
24. Karlsson Hedestam, G., et al. 2008. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6:143-155.
25. Kazzaz, J., J. Neidleman, M. Singh, G. Ott, and D. O'Hagan. 2000. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control. Release 67:347-356.
26. Koff, R. 2002. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine 20:3695-3701.
27. Lata, S., A. Reichel, R. Brock, R. Tampe, and J. Piehler. 2005. High-affinity adaptors for switchable recognition of histidine-tagged proteins. J. Am. Chem. Soc. 127:10205-10215.
28. Lian, T., T. Bui, and R. Ho. 1999. Formulation of HIV-envelope protein with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses. Vaccine 18:604-611. (Pubitemid 29509843)
29. Liang, M., N. Davies, J. Blanchfield, and I. Toth. 2006. Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr. Drug Deliv. 3:379-388.
30. Lowy, D., and J. Schiller. 2006. Prophylactic human papillomavirus vaccines. J. Clin. Invest. 116:1167-1173.
31. Montero, M., N. van Houten, X. Wang, and J. Scott. 2008. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 72:54-84.
32. O'Hagan, D., and N. Valiante. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2:727-735.
33. Oussoren, C., and G. Storm. 2001. Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Deliv. Rev. 50:143-156.
34. Pace, C., F. Vajdos, L. Fee, G. Grimsley, and T. Gray. 1995. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4:2411-2423.
35. Patel, J., R. O'Carra, J. Jones, J. Woodward, and R. Mumper. 2007. Preparation and characterization of nickel nanoparticles for binding to His-tag proteins and antigens. Pharm. Res. 24:343-352.
36. Perrie, Y., A. Mohammed, D. Kirby, S. McNeil, and V. Bramwell. 2008. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 364:272-280.
37. Platt, V., et al. 2010. Influence of multivalent nitrilotriacetic acid lipid-ligand affinity on the circulation half-life in mice of a liposome-attached His6-protein. Bioconjug. Chem. 21:892-902.
38. Rees, A., et al. 1993. The effect of lipoylation on CD4 T-cell recognition of the 19,000 MW Mycobacterium tuberculosis antigen. Immunology 80:407-414.
39. Rouillard, J., et al. 2004. Gene2Oligo: oligonucleotide design for in vitro synthesis. Nucleic Acids Res. 32:W176-W180.
40. Shcherbo, D., et al. 2007. Bright far-red fluorescent protein for whole-body imaging. Nat. Methods 4:741-746. (Pubitemid 47338169)
41. Shek, P., and T. Heath. 1983. Immune response mediated by liposome-associated protein antigens. III. Immunogenicity of bovine serum albumin covalently coupled to vesicle surface. Immunology 50:101-106.
42. Singh, M., et al. 2004. Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not. Pharm. Res. 21:2148-2152.
43. Singh, M., et al. 1997. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine 15:475-481. (Pubitemid 27188615)
44. Van Broekhoven, C., and J. Altin. 2005. The novel chelator lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA3-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulatory signals to T cells. Biochim. Biophys. Acta 1716:104-116.
45. Van Broekhoven, C., and J. Altin. 2001. A novel system for convenient detection of low-affinity receptor-ligand interactions: chelator-lipid liposomes engrafted with recombinant CD4 bind to cells expressing MHC class II. Immunol. Cell Biol. 79:274-284.
46. Van Rhijn, I., et al. 2009. CD1c bypasses lysosomes to present a lipopeptide antigen with 12 amino acids. J. Exp. Med. 206:1409-1422.
47. Watson, D., and F. C. Szoka. 2009. Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41. Vaccine 27:4672-4683.
48. Watson, D. S., Z. Huang, and F. C. Szoka, Jr. 2009. All-trans retinoic acid potentiates the antibody response in mice to a lipopeptide antigen adjuvanted with liposomal lipid A. Immunol. Cell Biol. 87:630-633.
49. Weissig, V., J. Lasch, A. Klibanov, and V. Torchilin. 1986. A new hydrophobic anchor for the attachment of proteins to liposomal membranes. FEBS Lett. 202:86-90.
50. Zhou, F., and L. Huang. 1993. Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. Vaccine 11:1139-1144.